Mussack T, Biberthaler P, Wiedemann E, Kanz K G, Englert A, Gippner-Steppert C, Jochum M
Chirurgische Klinik, Kliniken Innenstadt, Ludwig-Maximilians-Universität, München, Germany.
Acta Neurochir Suppl. 2000;76:393-6. doi: 10.1007/978-3-7091-6346-7_81.
Due to its neural tissue specificity S-100b is considered as a screening marker of cerebral injury in head trauma patients. However, the occurrence and relevance of an increased S-100b serum level in minor head trauma (MHT) is still debated. Therefore, the purpose of our study was to evaluate the diagnostic utility of S-100b measurements in a level I trauma center emergency room (ER). Eighty patients presenting with clinical symptoms of MHT (GCS score of 13-15, transitory loss of consciousness, amnesia, nausea) were prospectively recruited. Blood samples were drawn at 0 h, 6 h and 24 h after admission, and a cerebral computed tomography (CT) was performed. The reference group consisted of 10 patients with severe head injury (GCS score < 8), the control group of 20 healthy volunteers. Concentrations of S-100b in serum were determined by an immunoluminometric assay. The results were compared with the plasma levels of polymorphonuclear (PMN) elastase as an established general trauma marker. In the MHT group, the S-100b serum level revealed 1.26 +/- 0.57 ng/ml at study entry (73.46 +/- 47.53 min after trauma). In comparison, the S-100b concentration was significantly elevated in patients with severe head trauma (5.26 +/- 1.65 ng/ml, p = 0.009), but no significant difference became evident in relation to the control group (0.05 +/- 0.01 ng/ml). Starting values of PMN elastase in plasma amounted to 66.40 +/- 14.92 ng/ml in severe trauma, and to 60.52 +/- 10.75 ng/ml in MHT showing significant differences only in relation to the control group (23.36 +/- 1.53 ng/ml). When correlated with the severity of the later clinical course, the first S-100b measurements exhibited steadily increasing values as demonstrated in MHT outpatients (0.29 +/- 0.11 ng/ml), MHT in-hospital patients (0.70 +/- 0.19 ng/ml) and MHT intensive care unit patients (5.03 +/- 3.18 ng/ml). PMN elastase levels revealed no significant differences concerning the three MHT subgroups. Thus, in contrast to the general trauma marker PMN elastase, assessment of the specific neuroprotein S-100b early after traumatic insult appears to be a promising laboratory marker for the prognosis of the severity of brain injury in MHT patients. Nevertheless, further investigations are required to better understand its predictive value.
由于其神经组织特异性,S-100b被认为是头部创伤患者脑损伤的筛查标志物。然而,轻度头部创伤(MHT)患者血清S-100b水平升高的发生率及其相关性仍存在争议。因此,我们研究的目的是评估在一级创伤中心急诊室(ER)检测S-100b的诊断效用。前瞻性招募了80例有MHT临床症状(格拉斯哥昏迷评分[GCS]为13 - 15分、短暂意识丧失、失忆、恶心)的患者。入院后0小时、6小时和24小时采集血样,并进行脑部计算机断层扫描(CT)。参照组由10例重度颅脑损伤患者(GCS评分<8分)组成,对照组为20名健康志愿者。采用免疫发光分析法测定血清中S-100b的浓度。将结果与作为既定的一般创伤标志物的多形核(PMN)弹性蛋白酶的血浆水平进行比较。在MHT组中,研究开始时(创伤后73.46±47.53分钟)S-100b血清水平为1.26±0.57 ng/ml。相比之下,重度颅脑损伤患者的S-100b浓度显著升高(5.26±1.65 ng/ml,p = 0.009),但与对照组(0.05±0.01 ng/ml)相比无明显差异。重度创伤患者血浆中PMN弹性蛋白酶的起始值为66.40±14.92 ng/ml,MHT患者为60.52±10.75 ng/ml,仅与对照组(23.36±1.53 ng/ml)相比有显著差异。当与后期临床病程的严重程度相关联时,首次S-100b检测值呈稳步上升,如MHT门诊患者(0.29±0.11 ng/ml)、MHT住院患者(0.70±0.19 ng/ml)和MHT重症监护病房患者(5.03±3.18 ng/ml)所示。PMN弹性蛋白酶水平在三个MHT亚组中无显著差异。因此,与一般创伤标志物PMN弹性蛋白酶不同,创伤后早期评估特异性神经蛋白S-100b似乎是预测MHT患者脑损伤严重程度的一个有前景的实验室标志物。然而,需要进一步研究以更好地了解其预测价值。